X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
ONC201 is a new drug candidate that kills cancer cells but not normal cells in laboratory studies and has been previously evaluated in a phase I clinical trial in advanced cancer patients.
Lead Product(s): ONC201
Therapeutic Area: Oncology Product Name: ONC201
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
At the outset, all patients will be treated with ONC201, combined with either paxalisib or panobinostat. The study employs an adaptive design, in which different arms will be opened and closed based on emerging preclinical and clinical data.
Lead Product(s): ONC201,Paxalisib
Therapeutic Area: Oncology Product Name: ONC201
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Pacific Pediatric Neuro-Oncology Consortium
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2021
Details:
ONC201 is an orally administered small molecule dopamine receptor D2 (DRD2) antagonist and caseinolytic protease (ClpP) agonist in late-stage clinical development for recurrent gliomas that harbor the H3 K27M mutation.
Lead Product(s): ONC201
Therapeutic Area: Oncology Product Name: ONC201
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Chimerix
Deal Size: $78.0 million Upfront Cash: $39.0 million
Deal Type: Acquisition January 08, 2021
Details:
Kazia Therapeutics has executed a Letter of Intent with the Pacific Pediatric Neuro-Oncology Consortium to launch a clinical trial of multiple therapies, including Kazia's investigational, paxalisib, in diffuse midline gliomas including diffuse intrinsic pontine glioma.
Lead Product(s): ONC201,Paxalisib
Therapeutic Area: Oncology Product Name: ONC-201
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Kazia Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration December 10, 2020
Details:
Should ONC201 be approved by the FDA for H3 K27M-mutant glioma, the Rare Pediatric Disease Designation may enable Oncoceutics to receive a Rare Pediatric Disease Priority Review Voucher.
Lead Product(s): ONC201
Therapeutic Area: Oncology Product Name: ONC201
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2020
Details:
The data presented at ASCO 2020 highlights the potential of ONC201 to address the substantial need for patients with H3 K27M-mutant glioma.
Lead Product(s): ONC201
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 28, 2020
Details:
Clinical trial provides Japanese patients with high-grade glioma immediate access to ONC201. Data from this study will be an important part of working toward a Japanese market approval for ONC201.
Lead Product(s): ONC201
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 01, 2020
Details:
With these new patents, Oncoceutics has more than 20 patents for ONC201 issued globally with 10 patents for ONC201 issued by the United States Patent Office.
Lead Product(s): ONC201
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
